These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1159 related articles for article (PubMed ID: 26467036)
1. Clinicopathological factors predicting early and late distant recurrence in estrogen receptor-positive, HER2-negative breast cancer. Yamashita H; Ogiya A; Shien T; Horimoto Y; Masuda N; Inao T; Osako T; Takahashi M; Endo Y; Hosoda M; Ishida N; Horii R; Yamazaki K; Miyoshi Y; Yasojima H; Tomioka N; Breast Cancer; 2016 Nov; 23(6):830-843. PubMed ID: 26467036 [TBL] [Abstract][Full Text] [Related]
2. Validation of CTS5 Model in Large-scale Breast Cancer Population and Combination of CTS5 and Ki-67 Status to Develop a Novel Nomogram for Prognosis Prediction. Ning L; Liu Y; He X; Han R; Xin Y; Zhao J; Liu X Am J Clin Oncol; 2024 May; 47(5):228-238. PubMed ID: 38131531 [TBL] [Abstract][Full Text] [Related]
3. Marked lymphovascular invasion, progesterone receptor negativity, and high Ki67 labeling index predict poor outcome in breast cancer patients treated with endocrine therapy alone. Kurebayashi J; Kanomata N; Shimo T; Yamashita T; Aogi K; Nishimura R; Shimizu C; Tsuda H; Moriya T; Sonoo H Breast Cancer; 2014 Mar; 21(2):214-22. PubMed ID: 22689016 [TBL] [Abstract][Full Text] [Related]
4. Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysis. Debled M; MacGrogan G; Brouste V; Mathoulin-Pelissier S; Durand M; Mauriac L Cancer; 2007 Jun; 109(11):2197-204. PubMed ID: 17450590 [TBL] [Abstract][Full Text] [Related]
5. High Ki-67 Expression and Low Progesterone Receptor Expression Could Independently Lead to a Worse Prognosis for Postmenopausal Patients With Estrogen Receptor-Positive and HER2-Negative Breast Cancer. Nishimukai A; Yagi T; Yanai A; Miyagawa Y; Enomoto Y; Murase K; Imamura M; Takatsuka Y; Sakita I; Hatada T; Miyoshi Y Clin Breast Cancer; 2015 Jun; 15(3):204-11. PubMed ID: 25600243 [TBL] [Abstract][Full Text] [Related]
6. Differential expression of progesterone receptor, FOXA1, GATA3, and p53 between pre- and postmenopausal women with estrogen receptor-positive breast cancer. Hosoda M; Yamamoto M; Nakano K; Hatanaka KC; Takakuwa E; Hatanaka Y; Matsuno Y; Yamashita H Breast Cancer Res Treat; 2014 Apr; 144(2):249-61. PubMed ID: 24549642 [TBL] [Abstract][Full Text] [Related]
7. Post-relapse survival in patients with the early and late distant recurrence in estrogen receptor-positive HER2-negative breast cancer. Ogiya A; Yamazaki K; Horii R; Shien T; Horimoto Y; Masuda N; Inao T; Hosoda M; Ishida N; Osako T; Takahashi M; Endo Y; Miyoshi Y; Yasojima H; Tomioka N; Yamashita H; Breast Cancer; 2017 May; 24(3):473-482. PubMed ID: 27628678 [TBL] [Abstract][Full Text] [Related]
8. Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials. Regan MM; Pagani O; Francis PA; Fleming GF; Walley BA; Kammler R; Dell'Orto P; Russo L; Szőke J; Doimi F; Villani L; Pizzolitto S; Öhlschlegel C; Sessa F; Peg Cámara V; Rodríguez Peralto JL; MacGrogan G; Colleoni M; Goldhirsch A; Price KN; Coates AS; Gelber RD; Viale G; Breast Cancer Res Treat; 2015 Nov; 154(2):275-86. PubMed ID: 26493064 [TBL] [Abstract][Full Text] [Related]
9. Differences in expression of the cancer stem cell marker aldehyde dehydrogenase 1 among estrogen receptor-positive/human epidermal growth factor receptor type 2-negative breast cancer cases with early, late, and no recurrence. Miyoshi Y; Shien T; Ogiya A; Ishida N; Yamazaki K; Horii R; Horimoto Y; Masuda N; Yasojima H; Inao T; Osako T; Takahashi M; Tomioka N; Endo Y; Hosoda M; Doihara H; Miyoshi S; Yamashita H; Breast Cancer Res; 2016 Jul; 18(1):73. PubMed ID: 27368476 [TBL] [Abstract][Full Text] [Related]
10. FOXA1 expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptor-positive breast cancer. Kawase M; Toyama T; Takahashi S; Sato S; Yoshimoto N; Endo Y; Asano T; Kobayashi S; Fujii Y; Yamashita H Breast Cancer; 2015 May; 22(3):308-16. PubMed ID: 23771556 [TBL] [Abstract][Full Text] [Related]
11. Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013. Ehinger A; Malmström P; Bendahl PO; Elston CW; Falck AK; Forsare C; Grabau D; Rydén L; Stål O; Fernö M; Acta Oncol; 2017 Jan; 56(1):68-74. PubMed ID: 27762648 [TBL] [Abstract][Full Text] [Related]
12. Breast cancer in young women: prognostic factors and clinicopathological features. Aryandono T; Harijadi ; Soeripto Asian Pac J Cancer Prev; 2006; 7(3):451-4. PubMed ID: 17059343 [TBL] [Abstract][Full Text] [Related]
13. Changes in the ER, PgR, HER2, p53 and Ki-67 biological markers between primary and recurrent breast cancer: discordance rates and prognosis. Nishimura R; Osako T; Okumura Y; Tashima R; Toyozumi Y; Arima N World J Surg Oncol; 2011 Oct; 9():131. PubMed ID: 22004841 [TBL] [Abstract][Full Text] [Related]
14. Adjuvant endocrine therapy in pre- versus postmenopausal patients with steroid hormone receptor-positive breast cancer: results from a large population-based cohort of a cancer registry. Inwald EC; Koller M; Klinkhammer-Schalke M; Zeman F; Hofstädter F; Lindberg P; Gerstenhauer M; Schüler S; Treeck O; Ortmann O J Cancer Res Clin Oncol; 2015 Dec; 141(12):2229-40. PubMed ID: 26253629 [TBL] [Abstract][Full Text] [Related]
15. Estrogen receptor, Progesterone receptor, HER2 status and Ki67 index and responsiveness to adjuvant tamoxifen in postmenopausal high-risk breast cancer patients enrolled in the DBCG 77C trial. Knoop AS; Lænkholm AV; Jensen MB; Nielsen KV; Andersen J; Nielsen D; Ejlertsen B; Eur J Cancer; 2014 May; 50(8):1412-21. PubMed ID: 24675287 [TBL] [Abstract][Full Text] [Related]
16. Discordance of hormone receptor, human epidermal growth factor receptor-2, and Ki-67 between primary breast cancer and synchronous axillary lymph node metastasis. Kinoe H; Yamanouchi K; Kuba S; Morita M; Sakimura C; Kanetaka K; Takatsuki M; Abe K; Yano H; Matsumoto M; Otsubo R; Hayashida N; Nagayasu T; Eguchi S J BUON; 2018 Dec; 23(7):60-66. PubMed ID: 30722113 [TBL] [Abstract][Full Text] [Related]
18. Factors associated with late recurrence after completion of 5-year adjuvant tamoxifen in estrogen receptor positive breast cancer. Lee ES; Han W; Kim MK; Kim J; Yoo TK; Lee MH; Lee KH; Kim TY; Moon HG; Im SA; Noh DY; Lee ES BMC Cancer; 2016 Jul; 16():430. PubMed ID: 27388210 [TBL] [Abstract][Full Text] [Related]
19. Prognostic Significance of Progesterone Receptor Expression in Estrogen-Receptor Positive, HER2-Negative, Node-Negative Invasive Breast Cancer With a Low Ki-67 Labeling Index. Ono M; Tsuda H; Yoshida M; Shimizu C; Kinoshita T; Tamura K Clin Breast Cancer; 2017 Feb; 17(1):41-47. PubMed ID: 27477822 [TBL] [Abstract][Full Text] [Related]
20. Absent progesterone receptor expression in the lymph node metastases of ER-positive, HER2-negative breast cancer is associated with relapse on tamoxifen. Snell CE; Gough M; Middleton K; Hsieh M; Furnas L; Seidl B; Gibbons K; Pyke C; Shannon C; Woodward N; Armes JE J Clin Pathol; 2017 Nov; 70(11):954-960. PubMed ID: 28416639 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]